11/15/2024 10:03 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/14/2024 7:41 AM | Arbutus Biopharma (Subject) Two Seas Capital LP (Filed by)
| Form SC 13G/A | |
11/06/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/15/2024 7:26 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/11/2024 3:07 PM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/01/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/10/2024 3:50 PM | Arbutus Biopharma (Subject) MORGAN STANLEY (Filed by)
| Form SC 13G | |
|
06/06/2024 10:16 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/05/2024 5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/28/2024 3:25 PM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/24/2024 3:07 PM | Arbutus Biopharma (Issuer) Torti Frank (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/22/2024 5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/17/2024 8:03 AM | Arbutus Biopharma (Subject) Whitefort Capital Management, LP (Filed by)
| Form SC 13D/A | |
05/09/2024 7:00 AM | Arbutus Biopharma (Subject) Whitefort Capital Management, LP (Filed by)
| Form SC 13D | |
05/02/2024 3:32 PM | Arbutus Biopharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/02/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 6:26 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/10/2024 3:05 PM | Arbutus Biopharma (Filer)
| Form DEF 14A | |
04/10/2024 3:06 PM | Arbutus Biopharma (Filer)
| Form DEFA14A | |
04/04/2024 7:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/29/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/12/2024 8:41 AM | Arbutus Biopharma (Subject) BlackRock Inc. (Filed by)
| Form SC 13G/A | |
02/05/2024 6:54 PM | Arbutus Biopharma (Issuer) McElhaugh Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 6:54 PM | Arbutus Biopharma (Issuer) Sofia Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 6:54 PM | Arbutus Biopharma (Issuer) HASTINGS DAVID C (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 6:55 PM | Arbutus Biopharma (Issuer) Sims Karen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 6:55 PM | Arbutus Biopharma (Issuer) Naftzger J. Christopher (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/04/2024 3:09 PM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/21/2023 7:00 AM | Arbutus Biopharma (Subject) Two Seas Capital LP (Filed by)
| Form SC 13G | |